@article{Florence Nguyen-Khac_Jerome Lambert_Elise Chapiro_Aurore Grelier_Sarah Mould_Carole Barin_Agnes Daudignon_Nathalie Gachard_Stéphanie Struski_Catherine Henry_Dominique Penther_Hossein Mossafa_Joris Andrieux_Virginie Eclache_Chrystèle Bilhou-Nabera_Isabelle Luquet_Christine Terre_Laurence Baranger_Francine Mugneret_Jean Chiesa_Marie-Joelle Mozziconacci_Evelyne Callet-Bauchu_Lauren Veronese_Hélène Blons_Roger Owen_Julie Lejeune_Sylvie Chevret_Hélène Merle-Beral_Véronique Leblond_2013, place={Pavia, Italy}, title={Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström’s macroglobulinemia}, volume={98}, url={https://haematologica.org/article/view/6637}, DOI={10.3324/haematol.2012.070458}, abstractNote={Waldenström’s macroglobulinemia is a disease of mature B cells, the genetic basis of which is poorly understood. Few recurrent chromosomal abnormalities have been reported, and their prognostic value is not known. We conducted a prospective cytogenetic study of Waldenström’s macroglobulinemia and examined the prognostic value of chromosomal aberrations in an international randomized trial. The main aberrations were 6q deletions (30%), trisomy 18 (15%), 13q deletions (13%), 17p (<em>TP53</em>) deletions (8%), trisomy 4 (8%), and 11q (<em>ATM</em>) deletions (7%). There was a significant association between trisomy of chromosome 4 and trisomy of chromosome 18. Translocations involving the <em>IGH</em> genes were rare (<5%). Deletion of 6q and 11q, and trisomy 4, were significantly associated with adverse clinical and biological parameters. Patients with <em>TP53</em> deletion had short progression-free survival and short disease-free survival. Although rare (<5%), trisomy 12 was associated with short progression-free survival. In conclusion, the cytogenetic profile of Waldenström’s macroglobulinemia appears to differ from that of other B-cell lymphomas. Chromosomal abnormalities may help with diagnosis and prognostication, in conjunction with other clinical and biological characteristics. <em>This trial is registered with <a href="http://Clinicaltrials.gov">Clinicaltrials.gov</a>, numbers <a class="external-ref external-ref-type-clintrialgov" href="/lookup/external-ref?link_type=CLINTRIALGOV&amp;access_num=NCT00566332&amp;atom=%2Fhaematol%2F98%2F4%2F649.atom">NCT00566332</a> and <a class="external-ref external-ref-type-clintrialgov" href="/lookup/external-ref?link_type=CLINTRIALGOV&amp;access_num=NCT00608374&amp;atom=%2Fhaematol%2F98%2F4%2F649.atom">NCT00608374</a></em&gt;.}, number={4}, journal={Haematologica}, author={Florence Nguyen-Khac and Jerome Lambert and Elise Chapiro and Aurore Grelier and Sarah Mould and Carole Barin and Agnes Daudignon and Nathalie Gachard and Stéphanie Struski and Catherine Henry and Dominique Penther and Hossein Mossafa and Joris Andrieux and Virginie Eclache and Chrystèle Bilhou-Nabera and Isabelle Luquet and Christine Terre and Laurence Baranger and Francine Mugneret and Jean Chiesa and Marie-Joelle Mozziconacci and Evelyne Callet-Bauchu and Lauren Veronese and Hélène Blons and Roger Owen and Julie Lejeune and Sylvie Chevret and Hélène Merle-Beral and Véronique Leblond}, year={2013}, month={Mar.}, pages={649-654} }